• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清瘦素和脂联素水平与多发性硬化症的疾病活动或治疗反应无关。

Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis.

机构信息

Department of Immunology and Transfusion Medicine, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway.

Department of Clinical Medicine, University of Bergen, Bergen, Norway; Norwegian Multiple Sclerosis Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway.

出版信息

J Neuroimmunol. 2018 Oct 15;323:73-77. doi: 10.1016/j.jneuroim.2018.07.011. Epub 2018 Jul 24.

DOI:10.1016/j.jneuroim.2018.07.011
PMID:30196837
Abstract

Adipokines secreted by fatty tissue have inflammatory properties and are suggested biomarkers of MS disease activity. To assess this, 88 MS patients were followed with nine repeated measurements of leptin and adiponectin and 12 magnetic resonance imaging (MRI) scans for two years; six months without any immunomodulatory treatment followed by 18 months during interferon-beta (IFNB) treatment. Serum levels of leptin dropped and adiponectin increased upon initiation of IFNB-therapy, but were not associated with clinical or MRI disease activity or with treatment response. Our findings indicate that leptin and adiponectin are not useful as biomarkers of MS disease activity.

摘要

脂肪组织分泌的脂肪因子具有炎症特性,被认为是多发性硬化症(MS)疾病活动的生物标志物。为了评估这一点,88 名 MS 患者接受了为期两年的 9 次瘦素和脂联素重复测量和 12 次磁共振成像(MRI)扫描;6 个月无任何免疫调节治疗,随后在干扰素-β(IFNB)治疗期间 18 个月。IFNB 治疗开始时,血清瘦素水平下降,脂联素水平升高,但与临床或 MRI 疾病活动或治疗反应无关。我们的研究结果表明,瘦素和脂联素不能作为 MS 疾病活动的生物标志物。

相似文献

1
Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis.血清瘦素和脂联素水平与多发性硬化症的疾病活动或治疗反应无关。
J Neuroimmunol. 2018 Oct 15;323:73-77. doi: 10.1016/j.jneuroim.2018.07.011. Epub 2018 Jul 24.
2
Adipokines are associated with pediatric multiple sclerosis risk and course.脂肪细胞因子与小儿多发性硬化症的风险和病程有关。
Mult Scler Relat Disord. 2019 Nov;36:101384. doi: 10.1016/j.msard.2019.101384. Epub 2019 Sep 5.
3
Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta.瘦素作为接受β-干扰素治疗的多发性硬化症患者疾病活动的标志物。
J Neuroimmunol. 2003 Jun;139(1-2):150-4. doi: 10.1016/s0165-5728(03)00154-1.
4
A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta.一种基于病变部位的方法来预测接受β-干扰素治疗的多发性硬化症患者的预后。
Mult Scler Relat Disord. 2016 Jul;8:99-106. doi: 10.1016/j.msard.2016.05.012. Epub 2016 May 17.
5
Antibodies to Epstein-Barr virus and MRI disease activity in multiple sclerosis.抗 Epstein-Barr 病毒抗体与多发性硬化症的 MRI 疾病活动度。
Mult Scler. 2014 Dec;20(14):1833-40. doi: 10.1177/1352458514533843. Epub 2014 May 19.
6
Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis.依欧洲药品管理局(EMA)标准或孤立的磁共振成像(MRI)活动预测的多发性硬化症中β-干扰素治疗失败
Mult Scler. 2014 Apr;20(5):566-76. doi: 10.1177/1352458513502399. Epub 2013 Sep 2.
7
Blood lymphocyte subsets identify optimal responders to IFN-beta in MS.血液淋巴细胞亚群可识别多发性硬化症中对 IFN-β 有最佳反应的患者。
J Neurol. 2018 Jan;265(1):24-31. doi: 10.1007/s00415-017-8625-6. Epub 2017 Oct 12.
8
Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis.二甲双胍和吡格列酮治疗对代谢综合征和多发性硬化的免疫影响。
JAMA Neurol. 2016 May 1;73(5):520-8. doi: 10.1001/jamaneurol.2015.4807.
9
A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis.一项针对多发性硬化症患者的随机、双盲、安慰剂对照试验,研究维生素 D3 作为干扰素 β-1b 的附加治疗。
J Neurol Neurosurg Psychiatry. 2012 May;83(5):565-71. doi: 10.1136/jnnp-2011-301876. Epub 2012 Feb 22.
10
Prognostic biomarkers of IFNb therapy in multiple sclerosis patients.多发性硬化症患者中干扰素β治疗的预后生物标志物。
Mult Scler. 2015 Jun;21(7):894-904. doi: 10.1177/1352458514555786. Epub 2014 Nov 12.

引用本文的文献

1
Impact of Lifestyle Interventions on Multiple Sclerosis: Focus on Adipose Tissue.生活方式干预对多发性硬化症的影响:聚焦脂肪组织。
Nutrients. 2024 Sep 14;16(18):3100. doi: 10.3390/nu16183100.
2
Oral Contraceptives Interact with Adiposity-Associated Markers in Patients with Multiple Sclerosis.口服避孕药与多发性硬化症患者的肥胖相关标志物相互作用。
J Clin Med. 2024 Jan 14;13(2):464. doi: 10.3390/jcm13020464.
3
Interaction of S100A6 Protein with the Four-Helical Cytokines.S100A6 蛋白与四螺旋细胞因子的相互作用。
Biomolecules. 2023 Sep 4;13(9):1345. doi: 10.3390/biom13091345.
4
Adipokines in multiple sclerosis patients are related to clinical and radiological measures.多发性硬化症患者的脂肪细胞因子与临床和影像学指标相关。
J Neurol. 2023 Apr;270(4):2018-2030. doi: 10.1007/s00415-022-11519-8. Epub 2022 Dec 23.
5
Ketogenic and Modified Mediterranean Diet as a Tool to Counteract Neuroinflammation in Multiple Sclerosis: Nutritional Suggestions.生酮饮食和改良地中海饮食作为对抗多发性硬化症神经炎症的工具:营养建议。
Nutrients. 2022 Jun 8;14(12):2384. doi: 10.3390/nu14122384.
6
Investigation of blood leptin and adropin levels in patients with multiple sclerosis: A CONSORT-clinical study.多发性硬化症患者血液瘦素和阿朵蛋白水平的研究:一项 CONSORT 临床研究。
Medicine (Baltimore). 2021 Sep 17;100(37):e27247. doi: 10.1097/MD.0000000000027247.
7
Adipokines as Immune Cell Modulators in Multiple Sclerosis.脂肪细胞因子作为多发性硬化症中的免疫细胞调节剂。
Int J Mol Sci. 2021 Oct 7;22(19):10845. doi: 10.3390/ijms221910845.
8
Obesity and Multiple Sclerosis-A Multifaceted Association.肥胖与多发性硬化症——多方面的关联
J Clin Med. 2021 Jun 18;10(12):2689. doi: 10.3390/jcm10122689.
9
Antioxidant and Anti-inflammatory Diagnostic Biomarkers in Multiple Sclerosis: A Machine Learning Study.抗氧化剂和抗炎性生物标志物在多发性硬化症中的应用:一项机器学习研究。
Mol Neurobiol. 2020 May;57(5):2167-2178. doi: 10.1007/s12035-019-01856-7. Epub 2020 Jan 22.